The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II open-label study of olutasidenib post-transplant maintenance therapy for patients with IDH1-mutated myeloid malignancies.
 
Jeremy Ramdial
No Relationships to Disclose
 
Kelly Chien
Honoraria - Abbvie
Consulting or Advisory Role - Rigel
 
Ruitao Lin
Consulting or Advisory Role - ITM Oncologics; Lilly; Merck Sharp & Dohme, LLC; Monte Rosa Therapeutics
 
Jennie Duong
No Relationships to Disclose
 
Rohtesh Mehta
Consulting or Advisory Role - Orca Bio
Research Funding - CSL Behring (Inst); Incyte (Inst); Kadmon (Inst)
 
Betul Oran
No Relationships to Disclose
 
Uday Popat
Consulting or Advisory Role - Daiichi Sankyo
Research Funding - Abbvie (Inst); Bayer (Inst); Incyte (Inst); Novartis (Inst); T Scan (Inst)
 
Partow Kebriaei
Honoraria - Kite, a Gilead company; Pfizer
Travel, Accommodations, Expenses - Kite, a Gilead company; Pfizer
 
Katy Rezvani
Consulting or Advisory Role - Avenge Bio; Bayer; Bit Bio Limited; Caribou Biosciences; GEMoaB; Innate Pharma; NAVAN Technologies; oNKo Innate; Replay Holdings; Shinobi Therapeutics; The Alliance for Cancer Gene Therapy ACGT; Virogen
Research Funding - Affimed Therapeutics; Pharmacyclics; Takeda
Patents, Royalties, Other Intellectual Property - License agreement and research agreement with Affimed which creates an institutional conflict of interest under MD Anderson policy.; License agreement and research agreement with Affimed which creates an institutional conflict of interest under MD Anderson policy. (Inst); License agreement and research agreement with Takeda to develop CB-CAR NK cells for the treatment of B-cell malignancies and other cancers, which creates an institutional conflict of interest under MD Anderson policy; License agreement and research agreement with Takeda to develop CB-CAR NK cells for the treatment of B-cell malignancies and other cancers, which creates an institutional conflict of interest under MD Anderson policy (Inst); Patent on generation of BKV CTLs for the treatment of HC or PML; Patent on generation of CAR NK cells
 
Gheath Alatrash
No Relationships to Disclose
 
George Chen
No Relationships to Disclose
 
Yago Nieto
Honoraria - Affimed Therapeutics
Research Funding - Affimed Therapeutics (Inst); AstraZeneca (Inst); Secura Bio (Inst)
 
Abhishek Maiti
Research Funding - Celgene (Inst); Chimeric Therapeutics (Inst); CytoMed Therapeutics (Inst); Indapta Therapeutics (Inst); Lin BioScience (Inst)
 
Nicholas Short
Honoraria - Amgen
Consulting or Advisory Role - Amgen; AstraZeneca; NGM Biopharmaceuticals; Novartis; Pfizer; Takeda
Research Funding - Astellas Pharma; Stemline Therapeutics; Takeda
 
Ghayas Issa
Consulting or Advisory Role - Abbvie; Kura Oncology; Novartis; NuProbe; Sanofi; Syndax
Research Funding - Astex Pharmaceuticals (Inst); Cullinan Oncology; Kura Oncology (Inst); Merck; Novartis (Inst); NuProbe (Inst); Syndax (Inst)
 
Gautam Borthakur
Consulting or Advisory Role - Abbvie; Argenx; BiolineRx; BioTheryX; Catamaran Bio; Nkarta; Novartis; PTC Therapeutics; Takeda; Treadwell Therapeutics
Research Funding - Abbvie (Inst); Arvinas (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); BiolineRx (Inst); BioTheryX (Inst); Bristol-Myers Squibb (Inst); Cellestia Biotech (Inst); Cyclacel (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen Scientific Affairs (Inst); Lilly (Inst); MedImmune (Inst); Mundipharma Research (Inst); Nkarta (Inst); Nkarta (Inst); Novartis (Inst); Oncoceutics (Inst); PTC Therapeutics (Inst); Ryvu Therapeutics (Inst); TCR2 Therapeutics (Inst); Treadwell Therapeutics (Inst); XBiotech (Inst)
 
Hagop Kantarjian
Honoraria - Abbvie; Amgen; Ascentage Pharma Group; Daiichih-Sankyo (Inst); Immunogen (Inst); Ipsen; KAHR Medical; Novartis; Pfizer; Shenzhen Target Rx
Consulting or Advisory Role - Abbvie
Research Funding - Abbvie (Inst); Amgen (Inst); Ascentage Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Lilly (Inst); Immunogen (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst)
 
Richard Champlin
No Relationships to Disclose
 
Elizabeth Shpall
Honoraria - Bayer
Consulting or Advisory Role - Adaptimmune; AXIO Research; Celaid Therapeutics; Fibrobiologics; Navan; NY Blood Center
Patents, Royalties, Other Intellectual Property - Affimed Therapeutics; Syena; Takeda
Travel, Accommodations, Expenses - Magenta Therapeutics; Novartis
 
Courtney Dinardo
Honoraria - Abbvie; Astellas Pharma; Bristol Myers Squibb Foundation; Daiichi Sankyo/Astra Zeneca; Ellipses Pharma; Genentech/Abbvie; GlaxoSmithKline; Schrodinger; SERVIER
Consulting or Advisory Role - Abbvie; AstraZeneca; Genmab; Molecular Partners; Rigel; Ryvu Therapeutics; Schrodinger; SERVIER
Research Funding - Abbvie; Astex Pharmaceuticals; BeiGene; Bristol-Myers Squibb/Celgene; Cleave Therapeutics; Foghorn Therapeutics; Immune-Onc Therapeutics; Jazz Pharmaceuticals; Loxo/Lilly; Remix Therapeutics; SERVIER